GLYCOPYRRONIUM

Information current as at: 1 June 2026

Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Axhidrox®
Form and strength:
Please search for and view the medicine's Public Summary Document (PSD) for more information
Submission sponsor:
ACTOR PHARMACEUTICALS PTY LTD
Condition/indication:
(therapeutic use)
  • Primary axillary hyperhidrosis
Listing requested:
Please see PSD for more information
Funding program:
Please see PSD for more information
Request authority level:
Please see PSD for more information
PBAC Submission type:
New PBS listing (–)
Comment:
--
Other PBAC consideration:
--

Progress Details

Submission received for:
November 2025 PBAC meeting
Opportunity for consumer comment:
Open 30/07/2025 and close 24/09/2025 (see PBS Website)
PBAC meeting:
Held on 05/11/2025
PBAC outcome published:
Recommended (see PBAC Outcomes)
Notice of intent submitted:
03/12/2025
Lodgement of required documentation:
15/01/2026
Acceptance of complete documentation:
Accepted
Agreement to listing arrangements:
Commenced on 25/02/2026
Status:
Finalised
Government processes:
Commenced on 02/03/2026
Medicine listed on the PBS:
01/05/2026 (see PBS schedule)

PBAC Outcome

PBAC Recommendation:
Please see the Outcomes from the relevant meeting for more information

Case ID
a1109
Page last updated
30 April 2026
v.9.19